达比加群酯治疗心肌梗死的效果及对患者凝血功能指标、炎症因子水平的影响

目的 探讨达比加群酯治疗心肌梗死的效果,以为临床该病的治疗提供参考.方法 选取2018年1月1日至2020年12月31日安康市中医医院收治的40例心肌梗死患者作为研究对象,以抽签法将其随机分为对照组和观察组,各20例.对照组给予常规治疗(阿司匹林肠溶胶囊、阿托伐他汀钙片、盐酸曲美他嗪片、注射用尿激酶),观察组在对照组基...

Effect of dabigatran etexilate on myocardial infarction and its influences on coagulation function indexes and inflammatory factors levels

Objective To investigate the effect of dabigatran etexilate on myocardial infarction, so as to provide reference for the clinical treatment of the disease. Methods A total of 40 patients with myocardial infarction treated in Ankang hospital of traditional Chinese medicine from January 1, 2018 to December 31, 2020 were selected and randomly divided into control group and observation group by drawing lots, with 20 cases in each group. The control group was given routine treatment(aspirin delayed-release capsules, atorvastatin calcium tablets, trimetazidine hydrochloride tablets,urokinase for injection), and the observation group was given dabigatran etexilate treatment on the basis of the control group. The clinical efficacy, coagulation function indexes, inflammatory factors levels and occurrence of adverse reactions were compared between the two groups. Results The total effective rate of treatment in the observation group was95.00%, which was higher than 70.00% in the control group, and the difference was statistically significant(P <0.05).Before treatment, there were no significant differences in prothrombin time(PT), thrombin time(TT), activated partial thromboplastin time(APTT) and fibrinogen(FIB) level between the two groups(P>0.05);after treatment, PT, TT and APTT of the two groups were longer than those before treatment, FIB level was lower than that before treatment, those in the observation group were better than the control group, and the differences were statistically significant(P<0.05). Before treatment, there were no significant differences in the monocyte chemoattractant protein-1(MCP-1), toll like receptor 4(TLR4) and high-sensitivity C-reactive protein(hs-CRP) levels between the two groups(P>0.05);after treatment, the MCP-1, TLR4 and hs-CRP levels in the two groups were lower than those before treatment, those in the observation group were lower than the control group, and the differences were statistically significant(P <0.05). There was no significant difference in the total incidence of adverse reactions between the two groups(P>0.05). Conclusion Dabigatran etexilate in the treatment of myocardial infarction has a better effect. It can ameliorate the coagulation function indexes and reduce the inflammatory factors levels of patients, with good safety, which is worthy of clinical promotion and application.